UroGen Pharma Analyst Price Targets - Benzinga

UroGen Pharma Ltd

URGNNASDAQ

Trade with Public

Trade with Public

$46.16

-0.70-1.49%

al cierre: Aug 21, 5:00 PM EST

$46.16

-0.70-1.49%

Premercado: 4:05 AM EST

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

UroGen Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for UroGen Pharma (URGN).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

7Buy

1Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$39Upside to Avg. PT-16.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 6, 2026	Guggenheim	Michael Schmitz	PT Raise	Buy	$42→$58
Aug 6, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$45→$75
Aug 5, 2026	TD Cowen	Tara Bancroft	PT Raise	Buy	$50→$60
Jul 21, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$32→$42
Jul 16, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform→Outperformer	$40→$50
Jun 3, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$45
May 18, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$45
May 11, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$40→$45
May 7, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$34→$40
Mar 31, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$33
Mar 2, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$33
Jan 23, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$33
Jan 5, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$33
Oct 27, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$40
Oct 27, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Oct 3, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Aug 19, 2025	Piper Sandler	Kelsey Goodwin	Initiate	Overweight	$36
Aug 11, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$50→$40
Aug 7, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Aug 5, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $45 to $75.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

TD Cowen analyst Tara Bancroft maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $50 to $60.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

Guggenheim analyst Brad Canino maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $32 to $42.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50

Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperformer and raises the price target from $40 to $50.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $45 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $45 price target.

Benzinga Newsdesk